Applied Relaxation for Vasomotor Symptoms
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Applied Relaxation for Vasomotor Symptoms in Postmenopausal Women - a Randomized, Controlled Trial|
- Hot flashes average number and severity [ Time Frame: Baseline to 12 week after "start of treatment" ]The average number and severity of hot flashes/24 hours in self-registered diaries during the 12th week
- Hot flashes [ Time Frame: Baseline to 3 months after "end of treatment" ]The average number and severity of hot flashes per 24 hours after 3 months follow-up.
- Hot flashes reduction of hot flashes [ Time Frame: Baseline to 3 months after "end of treatment" ]The reduction of hot flashes in women defined as responders. Responders are defined as women with ≥50% reduction of hot flashes.
- Health Related Quality of Life [ Time Frame: Baseline to 3 months "end of treatment" ]The total score in the Women Health Questionnaire measured at 12th week and after 3 months follow-up.
- Adverse Events [ Time Frame: Baseline to 3 months "end of treatment" ]Adverse events documented by means of using open-ended questions at each contact.
- Salivary cortisol [ Time Frame: Baseline to 3 months after "end-of-treatment" ]Three samples of salivary cortisol (at awakening, 30 minutes after awakening, and at bedtime)were collected at baseline, after 12 weeks and 3 months after "end-of-treatment"
|Study Start Date:||March 2007|
|Study Completion Date:||September 2010|
|Primary Completion Date:||September 2010 (Final data collection date for primary outcome measure)|
|Experimental: Applied Relaxation (AR)||
Behavioral: Applied Relaxation (AR)
AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.
During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.
The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation.
No Intervention: Untreated Control Group (CG)
The women assigned to CG will be told to act as an untreated control group i.e. not to use hormonal treatment, other alternative medication, natural remedies for hot flashes and even not acupuncture, mind-body therapies or intensive physical activity.
Approximately 70% of women in Europe and North America experience hot flashes and night sweats during the climacteric period. Many women abstain from hormonal therapy because of side effects or contraindications such as breast cancer or thrombosis.
Different alternative therapies for alleviation of hot flashes are described in the literature. Both pharmacological treatments, different types of natural remedies, acupuncture, life-style changes and mind-body therapies are suggested as promising therapies. Applied relaxation (AR) is a technique influenced on cognitive behavioral therapy (CBT) using coping mechanism and conditioning. Previous study with healthy postmenopausal women showed promising results on hot flash frequency with an average decrease of more than 70 % with persisting effect three months after therapy and also HRQoL significantly increased probably due to better sleep and diminished vasomotor symptoms. But the method must be further investigated before strong evidence-based conclusion can be drawn.
Cortisol is a potent stress hormone regulated by the hypothalamic-pituitary axis. The factors underlying how alternative treatment works and the mechanism underlying improvements in symptoms are not fully understood.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01488864
|University Hospital, Dept of Obstetrics and Gynecology|
|Linköping, Sweden, 5851 85|
|Principal Investigator:||Elizabeth Nedstrand, Md, PhD||Ostergotland CC, University Hospital Dept. of Obstetrics and Gynecology, 582 85 Linköping, Sweden|